Follicular lymphoma grade I, extranodal and solid organ sites
ICD-10 C82.09 is a billable code used to indicate a diagnosis of follicular lymphoma grade i, extranodal and solid organ sites.
Follicular lymphoma grade I is a type of non-Hodgkin lymphoma characterized by the proliferation of follicle center (germinal center) B-cells. This subtype is typically indolent, meaning it progresses slowly, and is often diagnosed at an advanced stage. Extranodal involvement indicates that the lymphoma has spread beyond the lymph nodes to other organs, which can include the spleen, liver, bone marrow, or gastrointestinal tract. Patients may present with B-symptoms such as fever, night sweats, and weight loss, which can indicate a more aggressive disease course. Diagnosis is confirmed through biopsy and histological examination, often requiring immunophenotyping to distinguish it from other lymphomas. Treatment protocols may include watchful waiting for asymptomatic patients, chemotherapy, immunotherapy, or targeted therapies, depending on the stage and symptoms. The prognosis varies, but many patients can achieve long-term remission with appropriate management.
Comprehensive clinical notes detailing diagnosis, staging, treatment plans, and follow-up.
Patients presenting with lymphadenopathy, splenomegaly, or B-symptoms.
Ensure accurate grading and staging documentation to support treatment decisions.
Detailed pathology reports including histological findings and immunophenotyping results.
Biopsy specimens from lymph nodes or extranodal sites.
Accurate reporting of lymphoma subtype and grade is critical for appropriate coding.
Used when administering chemotherapy for follicular lymphoma.
Document the type of chemotherapy, dosage, and patient response.
Oncology specialists must ensure accurate coding of chemotherapy regimens.
Common treatments include watchful waiting for asymptomatic patients, chemotherapy regimens such as CHOP or R-CHOP, and targeted therapies like rituximab. The choice of treatment depends on the stage of the disease and the presence of B-symptoms.